PNC Financial Services Group
NTLA icon

PNC Financial Services Group’s Intellia Therapeutics NTLA Stock Holding History

PNC Financial Services Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.7K Sell
2,346
-1,206
-34% -$16.9K ﹤0.01% 3465
2026
Q1 		$45.5K Buy
3,552
+948
+36% +$12.1K ﹤0.01% 3266
2025
Q4 		$23.4K Sell
2,604
-2,334
-47% -$32.1K ﹤0.01% 3593
2025
Q3 		$85.3K Buy
4,938
+668
+16% +$8.23K ﹤0.01% 2910
2025
Q2 		$40.1K Sell
4,270
-2,006
-32% -$16.5K ﹤0.01% 3234
2025
Q1 		$44.6K Buy
6,276
+1,049
+20% +$10.6K ﹤0.01% 3165
2024
Q4 		$60.9K Sell
5,227
-11,633
-69% -$182K ﹤0.01% 2981
2024
Q3 		$346K Buy
16,860
+536
+3% +$12.4K ﹤0.01% 1794
2024
Q2 		$365K Buy
16,324
+368
+2% +$8.76K ﹤0.01% 1711
2024
Q1 		$439K Buy
15,956
+5,395
+51% +$150K ﹤0.01% 1615
2023
Q4 		$322K Buy
10,561
+7,151
+210% +$206K ﹤0.01% 1807
2023
Q3 		$108K Sell
3,410
-357
-9% -$13.8K ﹤0.01% 2527
2023
Q2 		$154K Buy
3,767
+260
+7% +$10.5K ﹤0.01% 2385
2023
Q1 		$131K Sell
3,507
-25
-0.7% -$981 ﹤0.01% 2400
2022
Q4 		$123K Buy
3,532
+35
+1% +$1.66K ﹤0.01% 2434
2022
Q3 		$198K Sell
3,497
-17
-0.5% -$1.05K ﹤0.01% 2091
2022
Q2 		$181K Sell
3,514
-4,043
-54% -$205K ﹤0.01% 2215
2022
Q1 		$549K Sell
7,557
-6,740
-47% -$571K ﹤0.01% 1588
2021
Q4 		$1.69M Sell
14,297
-3,513
-20% -$440K ﹤0.01% 1035
2021
Q3 		$2.39M Sell
17,810
-782
-4% -$118K ﹤0.01% 853
2021
Q2 		$3.01M Buy
18,592
+36
+0.2% +$2.8K ﹤0.01% 790
2021
Q1 		$1.49M Buy
18,556
+198
+1% +$13.3K ﹤0.01% 1007
2020
Q4 		$998K Buy
18,358
+5,000
+37% +$182K ﹤0.01% 1126
2020
Q3 		$266K Buy
13,358
+658
+5% +$13.7K ﹤0.01% 1764
2020
Q2 		$266K Sell
12,700
-10,000
-44% -$170K ﹤0.01% 1772
2020
Q1 		$278K Buy
22,700
+2,700
+14% +$36.4K ﹤0.01% 1627
2019
Q4 		$294K Buy
20,000
+10,950
+121% +$152K ﹤0.01% 1823
2019
Q3 		$120K Sell
9,050
-950
-10% -$15.1K ﹤0.01% 2437
2019
Q2 		$164K Sell
10,000
-485
-5% -$7.62K ﹤0.01% 2278
2019
Q1 		$179K Buy
10,485
+485
+5% +$7.23K ﹤0.01% 2206
2018
Q4 		$136K Buy
+10,000
New +$186K ﹤0.01% 2289
2017
Q4 		– Sell
-100
Closed -$2K – 4211
2017
Q3 		$2K Hold
100
– – ﹤0.01% 4015
2017
Q2 		$2K Hold
100
– – ﹤0.01% 3997
2017
Q1 		$2K Hold
100
– – ﹤0.01% 3953
2016
Q4 		$2K Hold
100
– – ﹤0.01% 3844
2016
Q3 		$2K Hold
100
– – ﹤0.01% 3822
2016
Q2 		$2K Buy
+100
New +$2.66K ﹤0.01% 4198

Other funds holding NTLA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return

PNC Financial Services Group's NTLA Position: Q2 2026 in Review

PNC Financial Services Group reduced its Intellia Therapeutics (NTLA) stake by 34% in Q2 2026, selling an estimated $16.9K and leaving 2,346 shares worth $39.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3465.

PNC Financial Services Group first reported a position in NTLA in Q2 2016 and has held it in 37 quarters since. The position peaked at $3.01M in Q2 2021. 142 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • PNC Financial Services Group held 2,346 shares of Intellia Therapeutics worth $39.7K as of Q2 2026.
  • PNC Financial Services Group sold 1,206 Intellia Therapeutics shares in Q2 2026, an estimated $16.9K.
  • Intellia Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #3465 holding.
  • PNC Financial Services Group first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 37 quarters since.
  • PNC Financial Services Group's Intellia Therapeutics position peaked at $3.01M in Q2 2021.
  • 142 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.